Table 2.
Antimicrobial susceptibility of strains used in this studya
| Strain | Antimicrobials |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIP | CAZ | FEP | IPM | MEM | FDC | GEN | AMK | LVX | CST | MIN | TGC | |
| OCU_Ac16a | ≥256 (R) | ≥256 (R) | ≥256 (R) | ≥512 (R) | ≥512 (R) | 32 (R); 6 mm (R) | 1 (S) | 8 (S) | 1 (S) | 0.094 (S) | 0.031 (S) | 0.25 (S) |
| OCU_Ac16b | ≥256 (R) | ≥256 (R) | 48 (R) | ≥512 (R) | ≥512 (R) | NA; 21 mm (S) | 0.75 (S) | 3 (S) | 1.5 (S) | 0.094 (S) | 0.031 (S) | 0.25 (S) |
| ATCC 19606T RFP50R | 24 (I) | 4 (S) | 8 (S) | 0.5 (S) | 2 (S) | ≤0.031 (S); 28 mm (S) | 12 (I) | 16 (S) | 0.38 (S) | 0.094 (S) | NT | NT |
| ATCC 19606T RFP50R with pOCU_Ac16a_2 | ≥256 (R) | ≥256 (R) | ≥256 (R) | ≥512 (R) | ≥512 (R) | 0.5 (S); 20 mm (S) | 8 (I) | 192 (R) | 0.25 (S) | 0.094 (S) | NT | NT |
| ATCC 19606T RFP50R with pOCU_Ac16a_3 | ≥256 (R) | 4 (S) | 8 (S) | 64 (R) | 32 (R) | ≤0.031 (S); 29 mm (S) | NT | NT | NT | NT | NT | NT |
PIP, piperacillin; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem; FDC, cefiderocol; GEN, gentamicin; AMK, amikacin; LVX, levofloxacin; CST, colistin; MIN, minocycline; TGC, tigecycline; S, susceptible; I, intermediate; R, resistant; NA, not applicable; NT, not tested.
a
MICs (mg/L) determined by performing Etest (for PIP, CAZ, FEP, GEN, AMK, LVX, and CST) or employing the microdilution method (for IPM, MEM, FDC, MIN, and TGC). The observed diameters of the zone of inhibition from FDC disc diffusion assays are shown.